Critical Appraisal of Cardiovascular Research
TAVR durability is of key importance. At TCT 2023 two new longer-term follow-up reports were published: PARTNER 3 at 5 years and Evolut Low-Risk at 4 years. A great friend … Continue reading Misleading graph or interpretation? Easier to blame the surgeons: TAVR durability trials at TCT 2023
Pablo Lamelas –PROTECTED TAVR study was presented in TCT 2022, bringing more discussion than ever for the use of Sentinel (cerebral embolic protection, CEP) during TAVR procedures. Many key opinion … Continue reading If you think PROTECTED TAVR is a NEGATIVE trial, you should read this: Cerebral protection (Sentinel) in TAVI
Pablo Lamelas – Last Thursday June 24th the first SOLACI/SIAC joint guideline was presented at ICBA Instituto Cardiovascular Rounds. Here we present a summary in English with outstanding faculty, an … Continue reading SOLACI/SIAC 2021 Guideline on the use of TAVI vs SAVR in Latin America: Presentation at ICBA Grand Rounds.
Pablo Lamelas – In the last decades multiple trials comparing the efficacy of PCI vs CABG incorporated repeat revascularization in the primary composite outcome, which favoured CABG repeatedly, and frequently … Continue reading Readdressing the validity of Repeat Revascularization outcome in PCI vs CABG trials
Fernando Botto – A general rule dictates “the more the antithombotic effect, the higher the risk of bleeding”. In stable CAD patients beyond 1 year of PCI or without prior … Continue reading NOACs in stable CAD with Atrial Fibrillation: with or without aspirin? The AFIRE trial
Pablo Lamelas – In TCT 2019 Dr Stone published the results of EXCEL trial at 5-years which triggered many controversies in TCT, EACTS, social media, etc. Does this 5-year report … Continue reading EXCEL 5-years: Trial-Based Vs Evidence-Based Medicine
Pablo Lamelas – In TCT 2019 two trials testing different TAVR designs were presented: SCOPE I (ACURATE neo vs Sapien 3) and Portico IDE trial (Portico vs other devices available). … Continue reading New TAVR studies: Weak design not the solution for small trials
Fernando Botto – ESC 2019 hot line sessions delivered us enough evidence to discuss methods and patient-centered decisions. For instance, dual antiplatelet treatment came up with a new trial in … Continue reading THEMIS trial: when significant is not significant
Pablo Lamelas – One of the top surprises from ESC congress 2019 was ISAR-REACT 5 trial, which concluded that in acute coronary syndromes Prasugrel was superior to Ticagrelor for efficacy … Continue reading Ticagrelor vs Prasugrel ISAR-REACT 5: A lesson learned
Pablo Lamelas – Hypertension is the largest responsible of death in the world. Its control and risk reduction is a health priority, specially middle- and low-income countries where risk factor … Continue reading Reducing cardiovascular risk in hypertension – HOPE-4 Trial
Pablo Lamelas – Multiple small randomized trials evaluating the effect of complete revascularization in STEMI suggested that complete revascularization was associated with a marked reduction (50%) in cardiovascular death, as … Continue reading Complete vs Culprit Only Revascularization after STEMI: Why do we need large trials like COMPLETE?
Pablo Lamelas – In the recent years several randomized trials comparing complete vs culprit-only revascularization were published, in which many of them were ¨positive¨. Then, do we have a definitive … Continue reading Complete vs culprit-only revascularization in STEMI
Pablo Lamelas – In 2016 two large randomized trials testing the role of PCI in left main (LM) disease were published, which seem inconsistent. Are they? what the body of … Continue reading PCI vs CABG for left main disease: EXCEL Vs NOBLE
Pablo Lamelas – AUGUSTUS was the last (until mid 2019) large randomized controlled trial evaluating antithrombotic therapy in patients with atrial fibrillation with indication of oral alticoagulation and concomitant indication … Continue reading Atrial fibrillation and PCI after AUGUSTUS
Pablo Lamelas – At ACC 2019 meeting two large randomized trials of patients at low-risk of Surgical Aortic Valve Replacement (SAVR): PARTNER 3 and EVOLUT low-risk. Here we summarize the … Continue reading TAVR in low-risk patients
CARDiOmics Club 